gate this matter further several sets of isomers of RSO₂-SR' and R'SO₂SR were prepared, as well as a number of other mixed and symmetrical thiolsulfonates to relate structure with antimicrobial activity.

The unsubstituted S-alkyl members were prepared by alkylation.⁷

$$RSO_2SK + R'Br \longrightarrow RSO_2SR' + KBr$$

The S-tosyl and S-trichlorovinyl esters were prepared by reacting the sulfenyl chloride with the sulfinate⁸

$$RSO_2M + C_7H_7SCl \longrightarrow RSO_2SC_7H_7 + MCl$$

where M is silver or zinc.

The bactericidal activity of these thiolsulfonates is given in Table I. A number of the compounds, namely those of lower molecular weight and the acetylenic derivatives, have high activity. Table II compares the

TABLE II									
BACTERIOSTATIC ACTIVITY OF THIOLSULFONATES									
$\mathrm{RSO}_2\mathrm{SR}'$									
R	R'	MID^{a}							
Symmetrical									
CH_3	CH_3	12							
C_8H_{17}	C_8H_{17}	40							
$C_{16}H_{33}$	$C_{16}H_{33}$	200							
C_7H_7	C_7H_7	500							
Unsymmetrical									
CH_3	C_8H_{17}	6							
C_8H_{17}	CH_3	12							
CH_3	$\mathrm{C}_{16}\mathrm{H}_{33}$	1000							
$C_{16}H_{33}$	CH_3	>1000							
CH_3	C_7H_7	40							
C_7H_7	CH_3	34							
C_8H_{17}	$C_{16}H_{33}$	250							
$C_{16}H_{33}$	C_8H_{17}	1000							
C_8H_{17}	C_7H_7	8							
C_7H_7	C_8H_{17}	0.3							
$\mathrm{C_{16}H_{33}}$	C_7H_7	200							
C_7H_7	$C_{16}H_{33}$	200							

^a Minimum inhibitory dose in parts per million to *Staphylococcus aureus*.

bacteriostatic action of a series of symmetrical thiolsulfonates and mixed isomers. It can be concluded from these data that the whole molecule enters into the toxic mechanism and that, although the toxicity toward bacteria of some of the isomers differs, neither the RSO₂- nor the RS- alone can be considered to be the active moiety. Table III presents data on a series of trichlorovinyl thiolsulfonates which were found to have very high bactericidal activity.

TA	BLE III

BACTERICIDAL ACTIVITY OF TRICHLOROVINYL THIOLSULFONATES								
$\mathrm{RSO}_2 \operatorname{SCCl}=\mathrm{CCl}_2$								

R	MLD^a
CH_3	2
C_2H_5	8
$n-C_{3}H_{7}$	8
$n-C_4H_9$	8
$n-C_8H_{17}$	250
C_6H_5	40

^a Minimum lethal dose in parts per million to *Staphylococcus* aureus.

(7) R. Otto, Ber., 13, 1282 (1880).

Experimental⁹

A.—The preparation of n-butyl p-toluenethiolsulfonate illustrates the general synthesis of the S-alkyl thiolsulfonates. To a 200-ml. two-necked flask was added a mixture of 12.2 g. (0.05 mole) of recrystallized potassium *p*-toluenethiolsulfonate, ¹⁰ 97 ml. of acetone, and 3 ml. of water. The salt was crushed in the solvents to insure small particle size. The flask was fitted with a stirrer, condenser, and heating mantle. To the flask was added at once 6.85 g. of *n*-butyl bromide and the mixture stirred and heated for 20 hr. After completion of the reaction the mixture was diluted with water and transferred to a 300-ml. separatory funnel. The heavy organic layer was removed, diluted with ether, and dried over sodium sulfate. Filtration of the ether solution and evaporation of the ether gave 10.5 g. of crude product. The compound was purified by thin layer chromatography by coating 20-cm. square glass plates to a thickness of 250 μ with silica gel. After activation of the plates by heating for 30 min. at 110°, the crude compound was applied by a small pipet about 2 cm. from the bottom edge, and the plate developed in a solvent mixture of benzene-petroleum ether-chloroform (8:8:1 by volume). After the solvent had risen to the top, the plates were removed, and one was sprayed with 10% sulfuric acid and charred at 110°. The position of the compound on the charred plate indicated where to remove the silica from the other plates. Ether extraction of the silica from 10-20 such plates and evaporation of the ether provided a sufficient amount of compound for analysis and microbiological testing. B.—The preparation of *p*-tosyl *n*-octanethiolsulfonate illus-

B.—The preparation of *p*-tosyl *n*-octanethiolsulfonate illustrates the synthesis of the S-tosyl thiolsulfonates. A 250-ml. erlenmeyer flask containing 50 ml. of absolute ether was set on a magnetic stirrer in the dark and 12.55 g. (0.044 mole, approx. 10% excess) of silver octanesulfinate¹¹ added. To the stirring suspension 6.85 g. (0.040 mole) of *p*-toluenesulfenyl chloride,¹² dissolved in 45 ml. of absolute ether, was added in small amounts over a period of 2–3 min. During the addition the temperature rose, causing the ether to boil and the orange-red solution of sulfenyl chloride to lose some of its color. After standing 15 min. in the dark the reaction mixture was filtered giving 9.5 g. of yellow solid; the theoretical requirement of silver chloride is 6.87 g. The pale yellow filtrate upon evaporation of the ether gave 8.8 g. of light yellow oil which was purified, as above, by thin layer chromatography.

The S-trichlorovinyl esters were made by reaction of the zinc sulfinate with 1,2,2,2-tetrachloroethanesulfenyl chloride which has been described elsewhere.¹³

Acknowledgment.—This work was supported by the National Institutes of Health under Grant A1-02793.

(9) Microanalyses were performed by G. Weiler and F. B. Strauss, Microanalytical Laboratories, Oxford, England. All melting points are corrected. Infrared spectra were run on a Perkin-Elmer Infracord.

(10) W. Spring, Ber., 7, 1157 (1874).

(11) T. Zinke, Ann., 412, 86 (1918).

(12) R. Lecher, with F. Holschneider, K. Köberle, W. Speer, and P. Stöcklin, Ber., 58, 409 (1925).

(13) S. S. Block and J. P. Weidner, submitted for publication.

Antiviral Compounds. IX. Steroid Derivatives

G. CAVALLINI,¹⁸ E. MASSARANI,^{1b} AND D. NARDI

Medicinal Chemistry Research Laboratories, Vister-Casatenovo Brianza (Como), Italy

Received May 4, 1964

In previous articles we had recorded the observation that a combination of a proper functional group with an appropriate radical may lead to compounds which display *in vivo* pharmacodynamic activities.²

(1) (a) Deceased. (b) Author to whom inquiries should be addressed, Research Division, Recordati S.p.A., Milan, Italy.

(2) G. Cavallini and E. Massarani, J. Med. Pharm. Chem., 1, 365 (1959).

⁽⁸⁾ B. G. Boldyrev, Dokl. Akad. Nauk SSSR. 131, 1331 (1960).

		nated eggs ^d			Tissu				
	Virueidal activity A-PR	Virustatie activity 8 virus	$MTD^b \gamma/ml.$	Virucid Polio type 1	al activity Vaccin	Virust Polio type 1	atic activity Vacciniaia	LD ₆₀ mg./kg.	Mice
I	0	0	50	0	0	0	0	1000	0
II	1	1	100	0	0	0	0	>1500	89
III	0	0	100	0	0	0	0	>1500	26
IV	1	0	100	0	0	0	0	>1500	58
V	7Δ	0	50	0	2Δ	0	1	>1500	0
V.I	7Δ	4Δ	50	0	2Δ	1	0	>1500	312Δ
VII	7Δ	2Δ	100	0	0	0	1	>1500	41
VIII	7Δ	1	100	0	0	0	0	>1500	86
IX	5Δ	1	100	0	0	0	0	>1500	0
Х	5Δ	3Δ	100	0	1	1	1	>1500	168Δ
XII	5Δ	0	50	0	0	0	0	1500	37
XIII	5Δ	0	50	0	0	1	1	1500	24
XIV	4Δ	1	25	0	0	0	1	1500	1484

^{*a*} The data which are statistically valid are indicated by Δ . ^{*b*} Maximal tolerated dose. ^{*c*} Difference between averages of the determinations of sorbitol-dehydrogenase activity (according to Gerlach) in the plasma of treated animals and in that of control animals. The significance was calculated by Student's "t." ^{*d*} The values are the differences of titers corresponding to logarithmic units.

TABLE II


Schiff's Bases and N,N-Diacetals of Steroidal Glyonals

		Yield,	М.р., °С.	Solvent of	Molecular						
No.	Compd.	%	dec.	crystn. ^a	composition	C	Н	N	\mathbf{C}	Н	N
IX	Δ4-Pregnen-21-al-3,20-dione N,N- <i>p</i> -carboxyanilino di- acetal	60	145 - 148	Е	$\mathrm{C}_{35}\mathrm{H}_{40}\mathrm{N}_{2}\mathrm{O}_{6}\cdot\mathrm{H}_{2}\mathrm{O}$	69.74	7.02	4.65	69.81	7.04	5.02
Х	Δ4-Pregnen-17-ol-21-al- 3,11,20-trione N,N- <i>p</i> -car- boxyanilino diacetal	50	155 - 158	Е	$\begin{array}{c} \mathrm{C}_{35}\mathrm{H}_{38}\mathrm{N}_{2}\mathrm{O}_{8}\cdot^{b}\\ \mathrm{C}_{2}\mathrm{H}_{5}\mathrm{OH}\cdot\mathrm{H}_{2}\mathrm{O}\end{array}$	65.45	6.83	4.13	65.70	7,11	4.00
XI	∆1,4-Pregnadien-17-ol-21-al- 3,11,20-trione N,N- <i>p</i> -car- boxyanilino diacetal	75	145- 146	E	${f C_{35}H_{36}N_2O_8}\cdot^b \ {f C_2H_5OH\cdot H_2O}$	65.66	6.55	4.14	65.63	6.49	4.13
XII	Δ4-Pregnene-3,11-dion-17-ol- 17-glyoxilidene cyclohexyl- amine ^e	92	$\frac{191 - }{192}$	E	$\mathrm{C}_{27}\mathrm{H}_{87}\mathrm{NO}_4$	73.77	8.48	3.19	73.51	8.31	3.12
XIII	∆1,4-Pregnadiene-3,11-dion- 17-ol-17-glyoxilidene cyclo- hexylamine	70	193	E	$\mathrm{C}_{27}\mathrm{H}_{85}\mathrm{NO}_4$	74.11	8.06	3.20	73.80	7.86	3.33
XIV	Δ4-Pregnene-3,11-dion-17-ol- 17-glyoxilidene <i>p</i> -aminophenol	66	204 - 205	d	$\mathrm{C}_{27}\mathrm{H}_{31}\mathrm{NO}_{5}$	72.14	6.95	3.12	72.19	6.82	3.02

^{*a*} E = ethanol. ^{*b*} Anal. Calcd.: C₂H₅O, 6.63. Found: C₂H₅O, 6.67. ^{*c*} The reaction was carried out for 2 hr. ^{*d*} The compound was obtained by evaporation *in vacuo* from ethanol at 20°; the residue was washed with ethyl ether.

By attaching suitable functional groups to hormonal structures, compounds with a wide variety of such activities were obtained,³ while the hormonal properties of the "supporting moiety" were abolished. Since we had also found that glyoxals derived from several polycyclic systems are active antiviral agents *in vivo*,⁴ we have studied α -ketoaldehydes V–VIII derived from steroid structures and compared them to the corresponding α -ketols (I–IV) whose hormonal activities are well known. In addition, several Schiff's bases and N,N-diacetals of the ketoaldehydes were also prepared and tested since a more potent and specific antiviral activity had been noted in other similarly protected glyoxal derivatives in other series.^{4a}

All the compounds were tested in embryonated chicken eggs against influenza virus Λ -PR8, in tissue cultures against type I poliomyelitis and vaccinia virus, and in mice against hepatitis MHV₃ virus (Craig strain). The methods employed have been



described previously.^{4b} The results are listed in Table I. None of the ketols (I–IV) exhibited antiviral activity under the conditions of the tests. By contrast, all the glyoxals and their Schiff's bases and N,Ndiacetals proved to be very active against influenza A-PR8 virus in chick embryos. Three of the com-

⁽³⁾ For references to this work, see G. Cavallini, H $Farmaco, \, {\bf 10}, \, \, {\bf 644}$ (1955).

^{(4) (}a) G. Cavallini, 2nd International Symposium on Chemotherapy, Naples, 1961, Vol. II, S. Karger, Basel, Switz., 1963, p. 36; (b) G. Rita, p. 36,

pounds (VI, VII, and X) were also virustatic. Compounds V and VI were virucidal against vaccinia in tissue culture; VI, X, and XIV showed activity against the hepatitis viral strain in mice. These results support the soundness of the assumption on which this research was planned, that ketoaldehydes derived from steroidal components would be antiviral.

Experimental⁵

All α -ketoaldehydes discussed in this note have been described in the literature. We prepared them in good yield by oxidation of the corresponding ketols with oxygen in aqueous methanol solution. Chemical and physical characteristics (especially infrared frequencies and rotatory indices) were in accord with literature data.

Preparation of Schiff's Bases and N,N-Diacetals .-- A mixture of the ketoaldehyde (1 mmole) and the respective primary amine (1-2 mmoles) in 10 ml. of ethanol was stirred at 20° for 24 hr., and the solution was concentrated until crystallization took place.

(5) All melting points are corrected.

The Preparation of Penicilloyl-Polylysines, Skin Test Reagents for the Clinical **Evaluation of Penicillin Hypersensitivity**

BERNARD B. LEVINE

Department of Medicine, New York University School of Medicine, New York, New York

Received A pril 3, 1964

The benzylpenicilloyl (BPO) group has been demonstrated to be the major haptenic antigenic determinant of benzylpenicillin (PG) hypersensitivity.¹⁻³ Multivalent benzylpenicilloyl-polylysine (BPO-PLL) conjugates have been found to be effective elicitors of allergic skin reactions of the wheal-and-flare reactions in a significant percentage of patients with histories of allergy to PG.^{2,3} These materials are accordingly promising skin test reagents for the clinical evaluation of penicillin hypersensitivity. Penicilloyl-PLL conjugates have been prepared previously by reaction of penicillenic acids with polylysine.¹⁻⁴ This procedure is tedious and results in conjugates contaminated with penicillenic acid groupings and with other impurities. This paper reports a new and simple method for the preparation of comparatively clean succinoylated multivalent penicilloyl-PLL(S) conjugates of different extents of conjugation directly from penicillins. This method is based on the known reaction of penicillins with aliphatic amines at high pH to form penicilloylamines.^{5,6} Parker and Thiel have recently published a method of preparation of maximally coupled,

unsuccinoylated penicilloyl-PLL conjugates based on this reaction.7

Table I shows the relation between mole ratios of reactants and the extents of conjugation of penicilloyl-PLL(S) conjugates which were prepared from PLL preparations of four different degrees of polymerization and from four different penicillins. Over 100 preparations have been made with similar results. Under the same conditions, penicillins were made to react with poly-p-lysine to form succinoylated multivalent penicilloyl-poly-p-lysine conjugates. This preparative method thus appears to be a general one.

The extents of conjugation listed in Table I are 7%too low, as 7% of the penicilloyl groups undergo N⁴thiazolidine acylation during the succinoylation reaction. N4-Acylated penicilloyl residues do not undergo the penamaldate reaction^{5,6} which is the basis of the penicilloyl assay. A maximum of only 60%of the NH_2 groups of PLL could be coupled with penicilloyl groups, probably because of steric interference from the bulky penicilloyl groups. Succinoylation, under the conditions given in the Experimental section, coupled at least 97% of the NH₂ groups, as determined by formol titrations.⁸ The conjugate solutions were found to be free from unreacted penicillins by bioassay⁹ and free from benzylpenicilloic acid by arsenomolybdate reduction.¹⁰ The ultraviolet absorption spectrum of benzylpenicilloyl-PLL(S) conjugates showed absorption peaks at 278 m μ which corresponds to the presence, in the conjugates, of penamaldoyl groups⁵ formed by rearrangement of penicilloyl groups.⁵ The optical densities at 280 m μ of some typical conjugate solutions indicate that 1 to 3% of the penicilloyl groups contained in the conjugates exist as the tautomeric penamaldate form. The absorption spectra show also superimposed peaks at λ 258 and 264 m μ corresponding to the benzyl side chain,⁵ and another peak at λ 268 m μ which may indicate trace quantities of penaldate groups.⁵ There were no detectible benzylpenicillenic acid disulfide chromophoric groupings detectible in the conjugate solutions as evidenced by the absence of absorption maxima in the 310–340 m μ region.⁵

Optical rotations of the conjugate solutions corrected for the contribution of succinoylated PLL yielded $[\alpha]^{25}$ D $+0.96^{\circ}$ for $1 \times 10^{-2}M$ benzylpenicilloyl contained in a typical benzylpenicilloyl-PLL(S) conjugate, a value in excellent agreement with the molar specific rotations of α -diastereoisomeric crystalline univalent benzylpenicilloylamines.⁶ This finding indicates that the penicilloyl groups contained in the conjugates prepared by the method given here are entirely, or predominantly, a-diastereoisomers, the expected diastereoisomeric product of the reaction of penicillins with amines at high pH.^{5,6} In contrast, penicilloylpolylysines prepared from penicillenic acids are diastereoisomeric mixtures.¹ Optical rotations of benzylpenicilloyl-PLL(S) solutions (BPO₈₀-PLL:₀₂(S) and BPO₆₀-PLL₂₈₆(S)) taken at decreasing pH showed

- (7) C. W. Parker and J. A. Thiel, J. Lab. Clin. Med., 62, 482 (1963).
 (8) A. W. Kenchington in "A Laboratory Manual of Analytic Methods in Protein Chemistry," P. Alexander and R. J. Block, Ed., Pergamon Press, New York, N. Y., 1960, p. 353.
- (9) D. G. Grove and W. H. Bandall, "Assay Methods of Antibiotics," Medical Encyclopedia. Inc., New York, N. Y., 1955, pp. 14-16.
 - (10) S. C. Pan, Anal. Chem., 26, 1438 (1954).

⁽¹⁾ B. B. Levine and Z. Ovary, J. Exptl. Med., 114, 875 (1961).

⁽²⁾ C. W. Parker, J. Shapiro, M. Kern, and H. N. Eisen, *ibid.*, 115, 821 (1962).

⁽³⁾ B. B. Levine, and V. H. Price, Immunology, in press.

⁽⁴⁾ B. B. Levine, J. Exptl. Med., 117, 161 (1963). (5)

[&]quot;Chemistry of Penicillin," H. T. Clarke, J. R. Johnson, and R. Robinson, Ed., Princeton University Press, Princeton, N. J., 1949.

⁽⁶⁾ B. B. Levine, J. Med. Pharm. Chem., 5, 1025 (1962).